

WHO Drug Information

Contents

General Policy Issues

WHO roundtable with the International Generic Pharmaceutical Alliance	61
Global partnerships for health	61
Role of the international generic pharmaceutical industry in public health	62

Reports on Individual Drugs

Short-course zidovudine in perinatal HIV transmission: more evidence and debate	65
Low-dose acetylsalicylic acid: risks of intracerebral haemorrhage?	66
Rotation of antimicrobials: possibilities for success	67

Current Topics

Ninth International Conference of Drug Regulatory Authorities: recommendations	72
Recommendations from the Ninth ICDRA	72
ICH and the common technical document (CTD)	78
Good clinical practice: application in tropical disease endemic countries	81

Biomedicines and vaccines

Biomedicines: meeting the challenges	84
Progress in biological standardization	86
Pertussis vaccines: WHO position	90

Regulatory Matters

Losartan and irbesartan: similar in advantage to ACE inhibitors	91
Variations in troglitazone assessments	91
Zolpidem and zopiclone dependence	91

Etanercept and sepsis	92
Clozapine and gastrointestinal obstruction	92
Orlistat for obesity	92
Trovaflaxacin and alatrofloxacin: CPMP recommends suspension	93
Trovaflaxacin and alatrofloxacin: FDA reports reservations in use	93
Control of misoprostol	93
Paracetamol: further warning	94
Metamizole sodium withdrawn	94
<i>Ginkgo biloba</i> suspended	94
Home test for hepatitis C	94
Urokinase: possible transmission of infectious agents	94
Astemizole voluntarily withdrawn	95
Polygeline: hypotension	95
Northern hemisphere influenza vaccine 1999–2000	95

ATC/DDD Classification

Final list	96
Temporary list	99

Essential Drugs

WHO Model Formulary:

Anti-allergics and drugs used in anaphylaxis	103
Chlorphenamine	104
Dexamethasone	105
Epinephrine (adrenaline)	105
Hydrocortisone	106
Prednisolone	106

Proposed International

Nonproprietary Names: List 81	107
--------------------------------------	-----